CTMX · CytomX Therapeutics
AI read · Neutral
The AI's read
This repeats the firm's existing view rather than adding company news. With no new target or company change reported, the update does not alter CytomX's outlook.
JP Morgan says CytomX Therapeutics is still a good investment.
Neutral
CytomX's favorable analyst rating was reaffirmed, but no new targets or company changes were reported. The update adds no new information that changes the company's outlook.
Get alerts for CTMX
Follow CytomX Therapeutics (CTMX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CTMXFree on the App Store and Google Play, or on the web.